Cargando…
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma
BACKGROUND: Cancer-associated fibroblasts (CAFs) are an important component of the tumour microenvironment. Recent studies revealed CAFs are heterogeneous and CAF subset(s) that suppress cancer progression (cancer-restraining CAFs [rCAFs]) must exist in addition to well-characterised cancer-promotin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867831/ https://www.ncbi.nlm.nih.gov/pubmed/35209871 http://dx.doi.org/10.1186/s12885-022-09272-2 |
_version_ | 1784656135203061760 |
---|---|
author | Mizutani, Yasuyuki Iida, Tadashi Ohno, Eizaburo Ishikawa, Takuya Kinoshita, Fumie Kuwatsuka, Yachiyo Imai, Miwa Shimizu, Shinobu Tsuruta, Toshihisa Enomoto, Atsushi Kawashima, Hiroki Fujishiro, Mitsuhiro |
author_facet | Mizutani, Yasuyuki Iida, Tadashi Ohno, Eizaburo Ishikawa, Takuya Kinoshita, Fumie Kuwatsuka, Yachiyo Imai, Miwa Shimizu, Shinobu Tsuruta, Toshihisa Enomoto, Atsushi Kawashima, Hiroki Fujishiro, Mitsuhiro |
author_sort | Mizutani, Yasuyuki |
collection | PubMed |
description | BACKGROUND: Cancer-associated fibroblasts (CAFs) are an important component of the tumour microenvironment. Recent studies revealed CAFs are heterogeneous and CAF subset(s) that suppress cancer progression (cancer-restraining CAFs [rCAFs]) must exist in addition to well-characterised cancer-promoting CAFs (pCAFs). However, the identity and specific markers of rCAFs are not yet reported. We recently identified Meflin as a specific marker of rCAFs in pancreatic and colon cancers. Our studies revealed that rCAFs may represent proliferating resident fibroblasts. Interestingly, a lineage tracing experiment showed Meflin-positive rCAFs differentiate into α-smooth muscle actin-positive and Meflin-negative CAFs, which are generally hypothesised as pCAFs, during cancer progression. Using a pharmacological approach, we identified AM80, a synthetic unnatural retinoid, as a reagent that effectively converts Meflin-negative pCAFs to Meflin-positive rCAFs. We aimed to investigate the efficacy of a combination of AM80 and gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with advanced pancreatic cancer. METHODS: The phase I part is a 3 + 3 design, open-label, and dose-finding study. The dose-limiting toxicity (DLT) of these combination therapies would be evaluated for 4 weeks. After the DLT evaluation period, if no disease progression is noted based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or if the patient has no intolerable toxicity, administration of AM80 with GEM and nab-PTX would be continued for up to 24 weeks. The phase II part is an open-label, single-arm study. The maximum tolerated dose (MTD) of AM80 with GEM and nab-PTX, determined in phase I, would be administered until intolerable toxicity or disease progression occurs, up to a maximum of 24 weeks, to confirm efficacy and safety. The primary endpoints are frequency of DLT and MTD of AM80 with GEM and nab-PTX in the phase I part and response rate based on the RECIST in the phase II part. Given the historical control data, we hope that the response rate will be over 23% in phase II. DISCUSSION: Strategies to convert pCAFs into rCAFs have been developed in recent years. We hypothesised that AM80 would be a promising enhancer of chemosensitivity and drug distribution through CAF conversion in the stroma. TRIAL REGISTRATION: Clinicaltrial.gov: NCT05064618, registered on 1 October 2021. jRCT: jRCT2041210056, registered on 27 August 2021. |
format | Online Article Text |
id | pubmed-8867831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88678312022-02-25 Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma Mizutani, Yasuyuki Iida, Tadashi Ohno, Eizaburo Ishikawa, Takuya Kinoshita, Fumie Kuwatsuka, Yachiyo Imai, Miwa Shimizu, Shinobu Tsuruta, Toshihisa Enomoto, Atsushi Kawashima, Hiroki Fujishiro, Mitsuhiro BMC Cancer Study Protocol BACKGROUND: Cancer-associated fibroblasts (CAFs) are an important component of the tumour microenvironment. Recent studies revealed CAFs are heterogeneous and CAF subset(s) that suppress cancer progression (cancer-restraining CAFs [rCAFs]) must exist in addition to well-characterised cancer-promoting CAFs (pCAFs). However, the identity and specific markers of rCAFs are not yet reported. We recently identified Meflin as a specific marker of rCAFs in pancreatic and colon cancers. Our studies revealed that rCAFs may represent proliferating resident fibroblasts. Interestingly, a lineage tracing experiment showed Meflin-positive rCAFs differentiate into α-smooth muscle actin-positive and Meflin-negative CAFs, which are generally hypothesised as pCAFs, during cancer progression. Using a pharmacological approach, we identified AM80, a synthetic unnatural retinoid, as a reagent that effectively converts Meflin-negative pCAFs to Meflin-positive rCAFs. We aimed to investigate the efficacy of a combination of AM80 and gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with advanced pancreatic cancer. METHODS: The phase I part is a 3 + 3 design, open-label, and dose-finding study. The dose-limiting toxicity (DLT) of these combination therapies would be evaluated for 4 weeks. After the DLT evaluation period, if no disease progression is noted based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or if the patient has no intolerable toxicity, administration of AM80 with GEM and nab-PTX would be continued for up to 24 weeks. The phase II part is an open-label, single-arm study. The maximum tolerated dose (MTD) of AM80 with GEM and nab-PTX, determined in phase I, would be administered until intolerable toxicity or disease progression occurs, up to a maximum of 24 weeks, to confirm efficacy and safety. The primary endpoints are frequency of DLT and MTD of AM80 with GEM and nab-PTX in the phase I part and response rate based on the RECIST in the phase II part. Given the historical control data, we hope that the response rate will be over 23% in phase II. DISCUSSION: Strategies to convert pCAFs into rCAFs have been developed in recent years. We hypothesised that AM80 would be a promising enhancer of chemosensitivity and drug distribution through CAF conversion in the stroma. TRIAL REGISTRATION: Clinicaltrial.gov: NCT05064618, registered on 1 October 2021. jRCT: jRCT2041210056, registered on 27 August 2021. BioMed Central 2022-02-24 /pmc/articles/PMC8867831/ /pubmed/35209871 http://dx.doi.org/10.1186/s12885-022-09272-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Mizutani, Yasuyuki Iida, Tadashi Ohno, Eizaburo Ishikawa, Takuya Kinoshita, Fumie Kuwatsuka, Yachiyo Imai, Miwa Shimizu, Shinobu Tsuruta, Toshihisa Enomoto, Atsushi Kawashima, Hiroki Fujishiro, Mitsuhiro Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
title | Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
title_full | Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
title_fullStr | Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
title_full_unstemmed | Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
title_short | Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
title_sort | safety and efficacy of mike-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase i/ii investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867831/ https://www.ncbi.nlm.nih.gov/pubmed/35209871 http://dx.doi.org/10.1186/s12885-022-09272-2 |
work_keys_str_mv | AT mizutaniyasuyuki safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT iidatadashi safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT ohnoeizaburo safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT ishikawatakuya safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT kinoshitafumie safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT kuwatsukayachiyo safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT imaimiwa safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT shimizushinobu safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT tsurutatoshihisa safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT enomotoatsushi safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT kawashimahiroki safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma AT fujishiromitsuhiro safetyandefficacyofmike1inpatientswithadvancedpancreaticcancerastudyprotocolforanopenlabelphaseiiiinvestigatorinitiatedclinicaltrialbasedonadrugrepositioningapproachthatreprogramsthetumourstroma |